Anileridine

CHEMBL1201347 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

352.5 g/mol

LogP

3.7

Phase

4

An opioid analgesic that binds to mu-opioid receptors in the brain and spinal cord to relieve moderate to severe pain. Like other opioids, it carries risks of respiratory depression, dependence, and tolerance.

Molecular Weight

352.5000 g/mol

LogP

3.70

TPSA

55.60 Å²

Lipinski RO5

Pass

Mechanism of Action

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1

InChI

InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3

Molecular Formula

C22H28N2O2

HBD / HBA

1 / 4

Rotatable Bonds

7

Heavy Atoms

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

An opioid analgesic that binds to mu-opioid receptors in the brain and spinal cord to relieve moderate to severe pain. Like other opioids, it carries risks of respiratory depression, dependence, and tolerance.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Anileridine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201347. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 8944. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Anileridine on PillFYI

Structure

Quick Data

Formula: C22H28N2O2

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.